PPP1R1A and melanoma: It can be speculated that the poor outcome that we here report in patients treated for advanced melanoma with combination therapy with BRAFi and MEKi and/or with CTLA-4i or PD-1i immunotherapy may be at least in part mediated by vitamin D deficiency-induced impairment of immune function.